Tests calcium delivered into the gut in people with type 2 diabetes
Tests calcium given directly into the small intestine in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes
Key facts
- Where
- Adelaide, AustraliaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06942195, who can take part
Where in Australia
- Clinical Research Facility, Adelaide Health and Medical Sciences BuildingAdelaide, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Adelaide
- Trial code
- NCT06942195
- Record updated
- 26 December 2025
- Original description
The intervention in this study consists of a 75-min intraduodenal infusion of an isotonic solution containing either of calcium chloride (CaCl2) or control (saline).Read full original descriptionShow less
Effects of Intraduodenal Calcium on Plasma Glucose, Glucoregulatory Hormones and Gastric Emptying in Response to a Mixed-nutrient Drink in Humans With Type 2 Diabetes
The intervention in this study consists of a 75-min intraduodenal infusion of an isotonic solution containing either of calcium chloride (CaCl2) or control (saline).
Participants enrolled into the study will receive, in randomised, double-blind fashion (i) Saline (control), (ii) 500 mg CaCl2, or (iii) 1000 mg CaCl2 in three separate sessions, each of which will be separated by at least 4 (and up to 10) days. Each study session will be 4-6 hours. Studies will be carried out in the Clinical Research Facility of the Adelaide Medical School, the University of Adelaide, by staff and students trained in the required techniques.
Inclusion: Males with type 2 diabetes mellitus (T2DM). Diagnosis of T2DM will be based on WHO criteria. Only males will be included to avoid the confounding effects of the menstrual cycle on gastric emptying; BMI: 28-38 kg/m²; HbA1c >=6.5 - <=7.9% at screening; Blood glucose medications will be required to be withheld for 48 hours prior to each study day; Weight-stable (i.e. <5% fluctuation) at study entry, which will be ascertained by a stable body weight in the preceding 3 months.
Exclusion: Use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, GI function, bodyweight or appetite (e.g. domperidone, cisapride, anticholinergic drugs (e.g. atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.); Individuals with low ferritin levels (<30 ng/mL), or who have donated blood in the 12 weeks prior to taking part in the study; Current use of recreational drugs, e.g. marijuana; Any patient whose medication cannot be withheld for 48 hours for medical reasons; Significant GI symptoms, or history of GI disease or surgery; Current gallbladder or pancreatic disease; Cardiovascular or respiratory diseases; Any other illnesses (except type 2 diabetes) as assessed by the investigator - (including chronic illnesses not explicitly listed above); Lactose intolerance/other food allergy(ies); HbA1c <6% or >7.9%; High performance athletes; Current intake of > 2 standard drinks on > 5 days per week (>140g/week); Current smokers of tobacco (cigarettes, cigars, pipes, sheesha, chewing, vaping etc.); Current intake of any illicit substance; Vegetarians; Inability to tolerate nasoduodenal tube; Inability to comprehend study protocol; Estimated glomerular filtration rate <45 ml/min.